Skip to content
Screener

Iovance Biotherapeutics, Inc. IOVA Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$99.3MBeat by $11.5M
EPS-$0.11Beat by $0.02
Revenue estimate$87.8M
EPS estimate-$0.13
“Based on our second-quarter performance and strong demand trends, we are reviewing our previously issued 2026 revenue guidance of $350 million to $370 million and will provide an update during the third quarter. Additionally, we continue to be excited by our clinical pipeline as lifileucel advances across other solid tumor indications including metastatic non-squamous non-small-cell lung cancer (NSCLC), the new registrational SARATOGA trial in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), and metastatic serous endometrial cancer. Continued manufacturing and operating efficiencies support our sustainable growth, accelerate progress toward profitability, and advance our clinical pipeline with first-in-class, novel products in new solid tumor indications.”
Frederick Vogt

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$110.1M
EPS estimate-$0.12

Financials

Q2 2026

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Cash & equivalents$110.8M-16.4%
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$4.47B+457%
Enterprise value$4.41B+509%
P/S13.8×+10.4×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp
FCF margin-91.2%-22.1pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Segments

By product

See full
Amtagvi$90.7M+67.8%
Proleukin$8.6M+46.2%

By segment

See full
Single Reportable$99.3M+65.7%

FAQ

When did Iovance Biotherapeutics, Inc. report Q2 2026 earnings?
Iovance Biotherapeutics, Inc. (IOVA) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Iovance Biotherapeutics, Inc.'s Q2 2026 revenue and EPS?
Iovance Biotherapeutics, Inc. reported revenue of $99.3M and eps of $-0.11 for Q2 2026.
Did Iovance Biotherapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $87.8M by $11.5M. EPS beat the consensus estimate of $-0.13 by $0.02.
How did Iovance Biotherapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 65.7% from $60.0M a year earlier and eps grew 66.7% from $-0.33.
Where can I find Iovance Biotherapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-091619) and the 10-Q periodic report (0001104659-26-091716) directly on SEC EDGAR. The filing index links above go to sec.gov.